<SEC-DOCUMENT>0001437749-23-016267.txt : 20230531
<SEC-HEADER>0001437749-23-016267.hdr.sgml : 20230531
<ACCEPTANCE-DATETIME>20230531161632
ACCESSION NUMBER:		0001437749-23-016267
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230531
DATE AS OF CHANGE:		20230531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268738
		FILM NUMBER:		23981207

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>nby20230531_424b3.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<html><head>
	<title>nby20230531_424b3.htm</title>

	<!-- Generated by ThunderDome Portal - 5/31/2023 3:52:27 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Filed Pursuant to Rule 424(b)(3)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No. 333-268738</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prospectus Supplement </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(To the Prospectus Dated</b>&nbsp;<b>December 15, 2022)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="pic1.jpg" src="pic1.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>1,548,502 Shares of Common Stock </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under that certain prospectus, dated December 15, 2022 (the &#8220;Prospectus&#8221;), filed as part of our registration statement on Form S-1 (File No. 333-268738), NovaBay Pharmaceuticals, Inc. (the &#8220;Company&#8221;) registered for resale, from time to time, by the selling stockholders named therein (&#8220;Selling Stockholders&#8221;) up to 1,548,502 shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), issuable upon: (i) the conversion of shares of our Series C Non-Voting Convertible Preferred Stock, par value $0.01 per share (the &#8220;Series C Preferred Stock&#8221;), (ii) the exercise of our short-term Series A-1 warrants to purchase Common Stock (the &#8220;Short-Term Warrants&#8221;), and (iii) the exercise of our long-term Series A-2 warrants to purchase Common Stock (the &#8220;Long-Term Warrants&#8221; and, together with the Short-Term Warrants, the &#8220;2022 Warrants&#8221;). The Series C Preferred Stock and the 2022 Warrants were issued by the Company to the Selling Stockholders in a private placement pursuant to a Securities Purchase Agreement, dated September 9, 2022, entered into by the Company and each of the Selling Stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus supplement (this &#8220;Supplement&#8221;) modifies, supersedes and supplements certain information contained or incorporated by reference in the Prospectus. This Supplement should be read in conjunction with the Prospectus, which is to be delivered with this Supplement. If there is any inconsistency between the information in the Prospectus and this Supplement, you should rely on the information in this Supplement. This Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, including any future amendments or supplements to it. You should read the entire Prospectus and any amendments or supplements carefully before you make an investment decision.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On November 15, 2022, we effected a 1-for-35 reverse stock split of our outstanding Common Stock (the &#8220;Reverse Stock Split&#8221;). All share numbers and share price data included in this Supplement have been adjusted to give effect to the Reverse Stock Split.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Common Stock is listed on the NYSE American under the symbol &#8220;NBY.&#8221; The last reported sale price of our Common Stock on May 30, 2023 was $0.65 per share.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Investing in our Common Stock involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described under the caption </b>&#8220;<b>Risk Factors</b>&#8221;<b> on page 8 of the Prospectus and in the documents incorporated by reference into the Prospectus and in any amendments or supplements to it.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this Supplement or the Prospectus. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023 PRIVATE PLACEMENT AND WARRANT AMENDMENT AGREEMENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As disclosed in the Company&#8217;s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on April 27, 2023 (the &#8220;Current Report&#8221;), we entered into a Securities Purchase Agreement (the &#8220;2023 Securities Purchase Agreement&#8221;) with certain existing accredited institutional investors (the &#8220;2023 Purchasers&#8221;) that provided for the issuance and sale in a private placement transaction (the &#8220;2023 Private Placement&#8221;) of (i) $3.3 million aggregate principal amount of Original Issue Discount Senior Secured Convertible Debentures Due November 1, 2024 (the &#8220;Debentures&#8221;), which may be converted or redeemed into up to an aggregate of 2,538,464 shares of Common Stock, (ii) new long-term Series B-1 warrants to purchase Common Stock, which are exercisable for up to an aggregate of 2,538,464 shares of Common Stock (&#8220;2023 Long-Term Warrants&#8221;), and (iii) new short-term Series B-2 warrants to purchase Common Stock, which are exercisable for up to an aggregate of 2,538,464 shares of Common Stock (the &#8220;2023 Short-Term Warrants&#8221; and together with the 2023 Long-Term Warrants, the &#8220;2023 Warrants&#8221;). The closing of the 2023 Private Placement occurred on May 1, 2023 (the &#8220;Private Placement Closing&#8221;). In connection with the Private Placement Closing, Common Stock purchase warrants that the Company previously issued to the 2023 Purchasers and to other existing investors in prior private placements and warrant reprice transactions who participated in the 2023 Private Placement were amended to lower the exercise price from $6.30 per share to $1.50 per share pursuant to a Warrant Amendment Agreement (&#8220;Warrant Amendment Agreement&#8221;). The Selling Stockholders who participated in the 2023 Private Placement, Armistice Capital Master Fund Ltd., Bigger Capital Fund, LP and District 2 Capital Fund LP, each entered into a Warrant Amendment Agreement. The 2022 Warrants held by the other Selling Stockholder who did not participate in the 2023 Private Placement and did not enter into a Warrant Amendment Agreement, will continue to have an exercise price of $6.30 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Since not all of the Selling Stockholders participated in the 2023 Private Placement, references in the Prospectus, as amended by this Supplement, to the exercise price shall be $1.50 only for the 2022 Warrants held by the Selling Stockholders listed above who were 2023 Purchasers, and references to the exercise price for all Warrants held by the Selling Stockholder that was not a 2023 Purchaser will remain as $6.30 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Additionally, the Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock (the &#8220;Series C Certificate of Designation&#8221;) provides for anti-dilution protections in the event that the Company grants any right to reprice any Company security or issue a new Company security that would entitle the holder to acquire Common Stock at an effective price per share that is lower than the conversion price of the Series C Preferred Stock, which is referred to as &#8220;full-ratchet&#8221; anti-dilution protection. As a result of the issuance of the Debentures at the conversion price of $1.30 and the 2023 Warrants having an exercise price at $1.30 per share, such anti-dilution protections were triggered resulting in the conversion price of each share of Series C Preferred Stock, which were convertible at a conversion price of $6.30 into 159 shares of Common Stock, being automatically adjusted downward to now be convertible at a conversion price of $1.30 into 770 shares of Common Stock. As a result of this conversion price adjustment, an additional 7,863,570 shares of Common Stock became issuable upon conversion of the outstanding Series C Preferred Stock, which additional shares will be registered under a separate resale registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Supplement is being filed to update the information in the Prospectus with the information summarized above and contained in the Current Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this prospectus supplement is May 31, 2023.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>pic1.jpg
<TEXT>
begin 644 pic1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !C <@# 2(  A$! Q$!_\0
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MW6E30P0V,DAC65I7VCYATZU\_AL//$58T:2NWHCWJM6-*#G-V2/H03[A]_\
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M^B>.)8B&71=!^]IL><_$GXB)\/=+N=4G4WVK:M<DH@&^:]DD;H>Y)8U^CO\
MP2<_X-X+[X_:=9_$[]IFRO+:SNV6YT7P6)2A:'&X/==P#P0GIUJA_P &Z_\
MP3=LOVFOBUK/Q]^(^B"^T7P[.MIX+MKR,/ ]PO+W.P\-M(P,\9S7[K1Z?(&W
M[LDJ!M)X'X_TK#BKBBM.L\)1TBM-/(OA/AFA1PT,377-4:N<W\,/A1X>^"_A
M2V\/>$]!TOP[HEG&([>ST^W6WB50,?PCD^YKII,HN[D =6ZM27LK6T0(^?M@
M\8KA/CI^T+X?_9^^'ESX@\2W@M;1'$$$29,M[._"0QCJSL<8 K\]]^K4]G"[
MDS[FK4C37-+8[::6.649R,\Y'?%-D'F@^N,*V./Q%?EE^U[\;_\ @H)XYGO/
M%O@&Q\*?"7P!IMH9H;.[BAU+4[U<Y#R!\A?EQD#ISFOFC]CS_@XQ^./P+^/<
M.A_M&?V3XF\#7<_DW6N:;IPMKK1VQ@$(G#)GKD<5]'2X4S&IA_K%)J26]M6>
M5_;N%E5]BVD^Q^[>IZ';:Y8R6]W;P7EO+P\,\8D208P>&R*_.C_@IW_P;?\
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M-/M-U!;B4X7S9 N[MQFHG\5:<%.W4+'@=#<)G^=?@S_P<)?'6[^._P"WW;>
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MO;9+H,/WZ^8&'3GK7LG_  3T^+Z?LS_M^?#;Q8[1QV&IW?\ 8VH22N0BI/\
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M9&_9_M;<XJY\6_A5XJ_9]^+&M^"/%]I%9Z_HKH\ODG,;QL,AE/3%4-/U,)=
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M,VV5SGY66JGBI,Z%9_\ 7];G.?\ IJM26N#N_NOP,U6\8 OIMHN>!>VX&/\
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M)_#B4G'X5\$?\''<2S_\%'?"<I(17\'KAB?^FS<8_&OP#A/_ )*^M3:UO/\
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M;L#7@%E=6^J;7M+A)%EPX[!0?KUKJ? 'Q%\5?!?QMI'BCPEK+:+KVDL3!=Q
M. #]Y6!Z@CBOU#,J&(K9=6HT'RSDK(_&LNKT<+F-.IB%=1>MS]S/AY_P1*_9
M<^']_P#:;3X-^&KBZ4[A+J.^YW$]3AR16A^U3X/^"O[$7[*/C'Q(W@KP5X=T
M^STR6*-;32H(GN)74JB+@;B2Q%?F%JO_  7B_:<?P9]CA7P''<,OEIJB6;-<
M!>F[83@FOFO]H3]JSXK?M5K96GQ/\<W/BI;&7S;>Q2W^S1H6](E^^1QC/3%?
MB.!X SR>)C4S&LXP3O?FO\C]VS#CC*G@Y0P5--M=$<5X;#W6DF=E:,32F9$?
MY6VL<@'Z=/PI/B??32^") RH(H98SQU^\*FT^7S=S>6[M&PAQZ$>W:H?B%:-
M<^"+T1HS2+)&67H!\ZYK^@Y?P)5%LHGX%AXSGF$92BU>2_,_J(^%0^T?"SPY
MM[:3:G)[_N5KR?\ X*+?LPK^UU^Q[XU\&V\,3:O?6#3:8TO(2ZCRR8],X*G_
M 'C7JWP:O(]5^$OAF:"1'BDTFU*.AX<>4M=!=6@C7@E03SCK^?\ GI7\3^WJ
M4,9[>#LXR?YG]A5:$,1A?92U32/Y2?"$\VBV7]FW:R)J&GRO:W<3C!CDCX.<
M^XKI+>TW6[2N-WF'>V1T/H/05])?\%L?V4IOV:/^"A5YXBLH$7PM\28/[2AC
M10%CN5 650/<_-^-?-T<C7;;$.!MW8K^O<AQZS#!4\4M;QO\T?R-Q5E\L!CY
MX>/4DOKCR]%NKAF"!%+$9X0XXQ7[._\ !O\ _LQ'X,_L:Q^+-2@1==^(=R=3
MD8CE(!\L*#T&WYL>IK\D?V:/@3<?M-?M,^"OAU DCKKNH(^H$#&RT0[I&Q]!
MC\:_I.\ >$-/\!^$M,T32[=+;3=+MX[2UA085(XU"@?ABOS/Q<SOV="EEE)Z
MRUD?IWA%DBYI8^JO0UK8[4 SDT5.8@O(%%?@Y^\GQY_P6!_X)KWW_!3#X,^'
M_#&E>*X_"%]X>U4:K%=2VYF23"E"I ^M?%%O_P &QWQ >-<_'*RSC.5T<@9_
M.OV:^SJ3G\:;]E7 Z\=.>E?293QAF^6X?ZKA)J,?0\3,.'<!C9\^(A=GY$?#
M+_@V\\6>!OBYX*\37WQ?M=2B\)ZW;:PUM_993[0L3ABN<\$U^MEM?&<$E=I]
M",$9S5PVZLN.<?6D2S2/IT]*X,YSS'9I5C6QL^:2.K+,JPV INEAHV3*=U;_
M &A2&"X(^7([U^8/[=?_  ;RS_M*_M/:S\0_ WQ"MO L>OHGVW37T\O&9A]Y
MUQCENIK]3&A##O2?9ER.O'O499FV*R^K[7"RLPQ^58;&1Y<1&Z/QKM/^#8OQ
MQ#$ WQLM.!SMTG.3^=/OO^#8GQAJB6T5Q\:+:2"&XBG<#2=NX(P;&<]>*_9+
MR1BFFT4MGGZ=J^AJ\?YW.#INKHUV/#I\$93":J*FDUJ8OA+2CH/AC3;#<TOV
M&VBMMY&-^Q N<>^*W(?]73?LP/<^M2*NP8KXS?WGNSZN*MHEH+1110417/W?
M7Z5YYXG_ &E_!/@?QO%X>USQ7H.AZM.VV*VU"[6W>8D94)OP'/T->BRC->4_
MM(_LB_#S]J[P@^B?$#PGI'B.R*L(Y+B$?:+,D8W12C#HP]0:(3AS6F[$5.=?
M >CVVIBXB1D:-XW^Y*IRK^F,<$'ZU'?W\=A$TTMU!;+CAI9,)^9Q7YAZS_P1
MT_:'_8^N+C4OV6/VC==M=+< 1^$_'#MJ%B%&6VQ2L21V ]C7AGQT_P""J?[<
M?[->A7NF?';]E;2?&N@V\B0SZAH\4KVLRG()S$6.6 Z\#FO4HY9&L_W4T_S,
MG4G%>\?I7\>_^"JO[/?[/#&/Q3\6/"D-Y'(T9L[*[%[=;U&2OEQ;B#]:^<8/
M^"E'QE_X*':X- _9V^&6O>$/"MS)Y5U\0O&-J;6W@@[RVMO]Z1B/NYXK\Q(?
M^"\GA?PWXD?5/!O[+_P/^&FO1!_-OM;M#<762,<C8&S]>:Y/XW_\%U?C5^T9
MX;ETW4?C5H/@[0I_W4FF^%+ V7[L#E5D^\!CTKZC*^%YTY*4Z2<NCD](^=NO
MWGBYCBVX..OR/U7^-/[6_P %O^"-GPSUPQ>(?^%C?&CQ#$QOIY;@7.I:E=8)
M#W&WB*('&$&.!7Y'_&/XS>(_VF/B?JGQ"\:SC4+_ %G;,\9R(8$Q\JIG^%<C
MCKQ7B>E_$KPI9:D%T>?4_&.O7YW(T$,M[?739ZDX+$Y]:^O_ -D'_@B]^T?^
MW[K-G)XET2[^#/PPR);B_P!5&S4=0B[K'">5.,X)  S7V&'Q.!R6$I^T4ZDM
MV^J_E79'YYC,HS#.)QP\(\E-/TN5?^"1O[&VM?M\?\%!O!NOV^G7#?"[X9WJ
MZEJ]]+&1;W%U%RD*GH6WX)[5_2A"<JPZG<2WL3VKR_\ 9#_9*\&_L:? [0O
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M("_:[R4$JFX@#@=R:^YR_P 1^(J/^RQGJNZU/E\=P;DV(?M:E--]S\;?!/\
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M3P6ZO)?W96WMT0?-N<[?E^AK^L>%L)_9F24E5T:6I_+W%V,AF6<VI:IGZ/\
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M^_9J^*WBJVMYM!T/Q3\1]5ETSPRR[4\.I&P5H=O\+$\D=L5Z9_P<$V/]J_\
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MCI[T442^!#?Q%=U"C  QZ8J6#E3TYZ\=:**YZ>US5_"1W'$H&!C'3%/@C5%
M"@ = !116\=_D9H?L SP/RJ(PH%^ZOY445A+^+%#6XJCMVQTH7Y7XXSUXHHJ
4X*T]!5=B;=1NHHKJ)#-%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
